Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability and PK of AZD4076 in Healthy Male Subjects
NCT02612662Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Nov 2015
- Primary completion
- Nov 2017
- Modality
- Small Interfering RNA (siRNA), Modified DNA Oligonucleotides, Single-strand DNA
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of RG-125 in Nonalcoholic steatohepatitis (NASH) (6 cohorts), sponsored by AstraZeneca. Primary endpoint: Safety and Tolerability assessed by vital signs, ECG, physical exam, labs, and AEs up to 16 weeks. Started Nov 2015; status: completed.
02
Drugs
RG-125
03
Conditions
Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT02612662.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02612662.